Elke Hoendermis

Cardiologist

Elke Hoendermis, (MD, PhD) is a cardiologist who is specialized in congenital heart disease, interventions in structural and congenital heart disease and in pulmonary hypertension.  She works as a Cardiologist in the University Medical Centre Groningen, The Netherlands since November 2001.

Hoendermis’ research is focused on invasive hemodynamics in pulmonary hypertension, heart failure and congenital heart disease and device interventions.

She takes part in several monocenter and multicenter studies on new medical and interventional treatment modalities in heart failure or congenital and structural heart diseases, such as treatment of PH in heart failure with advanced PH targeting medication or treatment of different kinds of heart diseases with implantation of cardiac devices. Other research projects are focused on hemodynamics in heart failure and in congenital abnormal heart anatomy such as the Fontan circulation.  Her main interest is to increase knowledge on hemodynamic changes in different heart diseases and device interventions as new treatment options.

Current activities

We are currently investigating the impact of different cardiac device implantations on hemodynamics, prognosis and quality of life of patients with heart failure or pulmonary hypertension. Ongoing projects are evaluating the effect of creation of a shunt between the two atria with a device, the implantation of a pulmonary pressure sensor in patients with heart failure to allow a novel way of home monitoring. Another randomized study focusses on the closure of the left atrial appendice in patients with atrial fibrillation and a contraindication for anticoagulation.

My publications

Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure with Preserved Ejection Fraction

Thomas M Gorter, Gijs van Woerden, Michiel Rienstra, Michael G Dickinson, Yoran M Hummel, Adriaan A Voors, Elke S Hoendermis, Dirk J van Veldhuisen. JACC Heart Fail 2020.

view on PubMed

Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.

Lam CS, Rienstra M, Tay WT, Liu LC, Hummel YM, van der Meer P, de Boer RA, Van Gelder IC, van Veldhuisen DJ, Voors AA, Hoendermis ES. JACC Heart Fail. 2017

view on publisher site

Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction.

Obokata M, Reddy YNV, Shah SJ, Kaye DM, Gustafsson F, Hasenfuβ G, Hoendermis E, Litwin SE, Komtebedde J, Lam C, Burkhoff D, Borlaug BA. J Am Coll Cardiol. 2019

view on publisher site

Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline.

Kuijpers T, Spencer FA, Siemieniuk RAC, Vandvik PO, Otto CM, Lytvyn L, Mir H, Jin AY, Manja V, Karthikeyan G, Hoendermis E, Martin J, Carballo S, O'Donnell M, Vartdal T, Baxter C, Patrick-Lake B, Scott J, Agoritsas T, Guyatt G.. BMJ. 2018

view on publisher site

One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial.

Shah SJ, Feldman T, Ricciardi MJ, Kahwash R, Lilly S, Litwin S, Nielsen CD, van der Harst P, Hoendermis E, Penicka M, Bartunek J, Fail PS, Kaye DM, Walton A, Petrie MC, Walker N, Basuray A, Yakubov S, Hummel SL, Chetcuti S, Forde-McLean R, Herrmann HC, Burkhoff D, Massaro JM, Cleland JGF, Mauri L. JAMA Cardiol. 2018

view on publisher site